254TiP ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer.
Saved in:
| Title: | 254TiP ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer. |
|---|---|
| Authors: | Lorusso, D.1, Xiang, Y.2, Colombo, N.3, Coleman, R.4, Randall, L.5, Duska, L.6, Hasegawa, K.7, Nogueira-Rodrigues, A.8, Cibula, D.9, Mirza, M.R.10, You, B.11, Oaknin, A.12, Christiaens, M.13, Taskiran, C.14, Sehouli, J.15, Korach, J.16, Marth, C.17, Keefe, S.18, Puglisi, M.18, Pignata, S.19 |
| Source: | Annals of Oncology. 2020 Supplement 6, Vol. 31, pS1341-S1342. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
